- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03569514
Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax
An Observational Clinical Study of AIGIV Use in Sporadic Cases of Systemic Anthrax
Study Overview
Detailed Description
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Gideon Akintunde, MD
- Phone Number: 204 275 4060
- Email: AkintundG@ebsi.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Confirmed or suspected systemic anthrax patients in the USA or other jurisdictions (if feasible) treated with AIGIV provided by the Centers for Disease Control and Prevention (CDC).
- Systemic anthrax defined as a clinically compatible case of gastrointestinal, injectional, or inhalational anthrax; anthrax meningitis or bacteremia; or cutaneous anthrax with systemic effects (i.e. tachycardia, tachypnea, hypotension, hyperthermia, hypothermia, leukocytosis) or with lesions that involve the head, neck or upper torso, or are large, bullous, multiple, or surrounded by significant edema PLUS confirmation by one of the following:
Epidemiologically linked to a documented anthrax environmental exposure. Laboratory confirmation by isolation of B. anthracis from an affected tissue or site.
Demonstration of B. anthracis antigens in tissues by immunohistochemical staining using both B. anthracis cell wall and capsule monoclonal antibodies.
Evidence of B. anthracis DNA; for example, by polymerase chain reaction (PCR) in specimens collected from a normally sterile site (such as blood or cerebrospinal fluid (CSF)) or lesion of other affected tissue(s) (skin, pulmonary, reticuloendothelial, or gastrointestinal).
QuickELISA™ Anthrax-PA kit manufactured by Immunetics, Inc. for detection of anti-PA antibodies in serum, plasma, and pleural/ascitic fluid.
RedLine Alert™ test manufactured by Tetracore, Inc., for identification of B. anthracis colonies.
- Informed consent/assent (as applicable).
Exclusion Criteria:
- There are no exclusion criteria for subjects enrolling in this study.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
AIGIV
Anthrax patients who have been administered AIGIV (ANTHRASIL®) as per licensed US prescribing information.
|
Anthrax Immune Globulin Intravenous (Human)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of AIGIV clinical benefit by overall mortality rate
Time Frame: Up to Day 30
|
Mortality rate (incidence of death) in patients with confirmed diagnosis of systemic anthrax treated with AIGIV
|
Up to Day 30
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of AIGIV safety by incidence of serious adverse drug reactions and serious suspected adverse drug reactions
Time Frame: Up to Day 30
|
Combined incidence of serious adverse drug reactions (i.e.
serious adverse events related to AIGIV administration) and serious suspected adverse drug reactions (i.e.
serious adverse events that occur during or within 24 hours following AIGIV administration) in individuals treated with AIGIV
|
Up to Day 30
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cause-specific mortality rate
Time Frame: Up to Day 30
|
Number of deaths assigned to a specific cause in patients with confirmed diagnosis of systemic anthrax treated with AIGIV
|
Up to Day 30
|
Mortality rate stratified by number of AIGIV doses administered
Time Frame: Up to Day 30
|
Number of deaths stratified by number of AIGIV doses (single versus multiple doses) in patients with confirmed diagnosis of systemic anthrax treated with AIGIV
|
Up to Day 30
|
Mortality rate stratified by AIGIV treatment time from symptom onset
Time Frame: Up to Day 30
|
Number of deaths stratified by AIGIV treatment time from symptom onset (early versus late onset of symptoms) in patients with confirmed diagnosis of systemic anthrax
|
Up to Day 30
|
Mortality rate stratified by acute physiologic assessment and chronic health evaluation (APACHE) II score at baseline
Time Frame: Up to Day 30
|
Number of deaths stratified by APACHE II score at baseline in patients with confirmed diagnosis of systemic anthrax treated with AIGIV
|
Up to Day 30
|
Duration of hospitalization
Time Frame: Up to Day 30
|
Length of hospitalization in patients with confirmed diagnosis of systemic anthrax treated with AIGIV
|
Up to Day 30
|
Duration of intensive care unit (ICU) hospitalization
Time Frame: Up to Day 30
|
Length of ICU stay in patients with confirmed diagnosis of systemic anthrax treated with AIGIV
|
Up to Day 30
|
Incidence of ICU hospitalization
Time Frame: Up to Day 30
|
Number of patients with confirmed diagnosis of systemic anthrax treated with AIGIV admitted to ICU
|
Up to Day 30
|
Duration of mechanical ventilation
Time Frame: Up to Day 30
|
Length of mechanical ventilation in patients with confirmed diagnosis of systemic anthrax treated with AIGIV
|
Up to Day 30
|
Evaluation of sequential organ failure assessment (SOFA) score
Time Frame: Up to Day 14
|
Increase in sequential organ failure assessment (SOFA) score from baseline in patients with confirmed diagnosis of systemic anthrax treated with AIGIV.
Total SOFA score can range from 0 to 24; increase in total SOFA score suggests worse clinical outcome prediction.
|
Up to Day 14
|
Assessment of AIGIV pharmacokinetics
Time Frame: Up to Day 7
|
Serum concentration of AIGIV over time in patients with confirmed diagnosis of systemic anthrax treated with AIGIV to determine pharmacokinetic parameters such as maximum serum concentration, area under the concentration versus time (i.e. level of AIGIV circulating over time) and clearance
|
Up to Day 7
|
Assessment of anthrax toxin levels (protective antigen and lethal factor)
Time Frame: Up to Day 7
|
Levels of anthrax toxins (protective antigen and lethal factor) over time in patients with confirmed diagnosis of systemic anthrax treated with AIGIV
|
Up to Day 7
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Brandon Essink, MD
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AX-003B
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anthrax
-
Elusys TherapeuticsCompletedInhalational AnthraxUnited States
-
Elusys TherapeuticsCompletedInhalational AnthraxUnited States
-
Emergent BioSolutionsCompletedAnthrax InfectionUnited States
-
Elusys TherapeuticsCompletedInhalational AnthraxUnited States
-
Elusys TherapeuticsCompletedInhalational AnthraxUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...CompletedBacillus Anthracis (Anthrax)United States
-
National Institute of Allergy and Infectious Diseases...Terminated
-
PharmAthene UK LimitedNational Institute of Allergy and Infectious Diseases (NIAID)CompletedBacillus Anthracis (Anthrax)United States
-
Emergent BioSolutionsDepartment of Health and Human ServicesCompletedSymptoms of Inhalational AnthraxUnited States
Clinical Trials on AIGIV
-
Emergent BioSolutionsDepartment of Health and Human Services; Centers for Disease Control and PreventionNot yet recruiting
-
Emergent BioSolutionsNational Institutes of Health (NIH)CompletedAnthraxUnited States